Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is poised for continued success and their stock is a solid investment opportunity based on their strong financial performance and promising future growth opportunities.

Bears say

Minimed Group is facing strong competition in the diabetes management market, particularly in the insulin pump and continuous glucose monitoring segments. Despite its strong clinical evidence and positive outcomes, the company's pricing power may be limited as payors look for more economically attractive solutions, which could compress margins in the future. Additionally, as more companies enter the market and increase competition, it is possible that payors may limit reimbursement or negotiate for tighter discounts. While Minimed Group has a strong track record of growth and profitability, it is important for the overall market for adoption of advanced diabetes technology to continue growing. However, there are risks such as intense competition, potential pricing headwinds, and shifting market dynamics that could impact the company's success.

MMED has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 11 analysts, MMED has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.